Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.
Outlook Therapeutics reported Nov. 27 that its ophthalmic bevacizumab candidate Lytenava (ONS-5010) did not meet its non-inferiority endpoint in topline results from the NORSE EIGHT trial vs. ranib...
Japan’s Astellas Pharma announced Nov. 19 that the US FDA had issued a complete response letter rejecting its supplemental new drug application (sNDA) for Izervay seeking to expand the drug’s label...
Harrow, of Nashville, Tennessee reported Nov. 13 that it had entered into a partnership with GoodRx to provide patients without insurance or for whom insurance is not a viable option a cash-pay alt...
France’s Nicox announced Nov. 19 that it had chosen the higher dose of NCX 470 ophthalmic solution to advance in the Phase III Mont Blanc trial in glaucoma. The company said both doses tested—0.065...
Alkeus Pharmaceuticals announced Nov. 18 that the US FDA had granted rare pediatric disease and fast track designations to gildeuretinol (ALK-001), its oral therapy candidate for Stargardt disease....
Harrow’s ImprimisRx subsidiary received a $34.9 million verdict on Nov. 20, 2024, in a trademark infringement lawsuit against OSRX Pharmaceuticals, of Missoula, Montana. OSRX is an affiliate of Ocu...
Lenz Therapeutics announced Oct. 21 that the US FDA had accepted its new drug application (NDA) for LNZ100, a once-daily, preservative-free eye drop candidate for presbyopia. The FDA assigned a Pre...
William Boyd, MD, deputy director of ophthalmology at the US FDA’s Office of New Drugs, had a quick answer when asked to name the biggest unmet need in ophthalmology. “We need and want more therapi...
The celebrations and excitement that accompanied the launch in 2023 of the first two drugs approved in the US for the treatment geographic atrophy (GA) gave way to a hangover and regrets at the 202...
Pine Pharmaceuticals, of Tonawanda, New York, stopped repackaging Avastin (bevacizumab) for ophthalmic use in October 2024, according to the American Academy of Ophthalmology and American Society o...
AbbVie, of North Chicago, Illinois, reported Oct. 30 that its Q3-2024 eye care net revenue was $525 million, a 13.5 percent decline (-11.2 percent cc) from $605 million in Q3-2023. Restasis revenue...
Taiwan-based Formosa Pharmaceuticals announced Oct. 31 that it had entered into an exclusive licensing agreement with DÁVI Farmacêutica, of Portugal, for the rights there to market clobetasol propi...
Japan’s Astellas Pharma announced Oct. 28 that it had withdrawn its marketing authorization application in the EU for avacincaptad pegol, a complement-5 inhibitor targeting geographic atrophy (GA) ...
Regeneron of Tarrytown, New York, reported Oct. 31 that its Q3-2024 US revenue for Eylea (aflibercept) 2 mg and Eylea HD (a higher dose of aflibercept at 8 mg) was $1.54 billion, a 3 percent increa...
Genentech, a member of the Roche Group, announced Oct. 18 positive topline one-year results from the postmarket Elevatum study evaluating Vabysmo (faricimab-svoa) for the treatment of diabetic macu...
Alkeus Pharmaceuticals reported positive topline results on Oct. 23 from the Phase III SAGA trial of gildeuretinol acetate (ALK-001), a once-daily oral therapy candidate targeting geographic atroph...
RevOpsis Therapeutics announced Oct. 15 that it had been awarded a Small Business Innovation Research grant of $1.8 million from the National Eye Institute (NEI) to advance lead asset RO-104 for ex...
South Korean companies GC Biopharma and Novelty Nobility announced Oct. 28 that they would jointly research and develop a novel treatment candidate for geographic atrophy (GA). The companies said a...
Pine Pharmaceuticals, of Tonawanda, New York, stopped repackaging Avastin (bevacizumab) for ophthalmic use in October 2024, according to the American Academy of Ophthalmology and American Society o...
Swiss company Roche reported Oct. 23 that Q3-2024 Vabysmo sales were CHF 1 billion ($1.15 billion, converted on Oct. 23, 2024), a 59 percent increase over CHF 656 million in Q3-2023. The company sa...
Los Angeles-based Spinogenix reported Oct. 16 that it was launching a program to evaluate SPG302 as a potential neuroprotective therapeutic for glaucoma. Spinogenix describes SPG302 as a once-a-day...
Orasis Pharmaceuticals announced Oct. 16 that it had licensed its Qlosi presbyopia drops to Optus Pharmaceuticals for the Korean market. Under the deal, Optus will pay upfront and milestone payment...
France’s Nicox announced Oct. 14 a deal with Soleus Capital under which Soleus will acquire Nicox’ royalties from the glaucoma treatment Vyzulta for $15 million, while providing $1.5 million in equ...
Eyenovia announced Sept. 26 the US launch and commercial availability of clobetasol propionate ophthalmic suspension 0.05%, known as Clobetasol, for postoperative inflammation and pain following oc...
Orasis Pharmaceuticals led recent ophthalmic fundraising efforts with $78 million in Series D and structured capital to support the launch of Qlosi drops for presbyopia. Financing announced in the ...
Europe’s Committee for Medicinal Products for Human Use (CHMP) announced Sept. 19 that AbbVie had withdrawn its marketing authorization application for the sustained-release glaucoma implant Duryst...
Researchers at the National Eye Institute (NEI), working with counterparts in China, have discovered a reversible cataract response in hibernating squirrels that may point toward a nonsurgical trea...
The negative opinion of Syfovre by a key EU regulatory committee has thrown the global marketing plans for complement inhibitors for GA into disarray. Two companies—Apellis Pharmaceuticals and Aste...
Eyenovia announced Sept. 26 the US launch and commercial availability of clobetasol propionate ophthalmic suspension 0.05%, known as Clobetasol, for postoperative inflammation and pain following oc...
Europe’s Committee for Medicinal Products for Human Use (CHMP) announced Sept. 19 that AbbVie had withdrawn its marketing authorization application for the sustained-release glaucoma implant Duryst...
Amgen reported Sept. 24 that Tepezza had gained approval in Japan for the treatment of active or high clinical activity score thyroid eye disease (TED). The Thousand Oaks, California, company said ...
The FDA has approved Amgen’s Pavblu (aflibercept-ayyh), making it the fifth Eylea biosimilar to reach the milestone in the US in 2024. FDA records show Pavblu was approved Aug. 23. Labeling shows i...
Harrow reported Sept. 25 that it is creating nearly 150 new jobs as it expands its corporate headquarters in Nashville, Tennessee. The move follows the company increasing its total leased space in ...
Ripple Therapeutics, of Toronto, Canada, announced Sept. 17 that it had signed a collaboration agreement with AbbVie to develop RTC-620, a fully biodegradable sustained-release intracameral bimatop...
Roche faced an ophthalmic patent cliff in the US before Regeneron. First, Roche introduced an extended duration alternative to its flagship inhibitor of vascular endothelial growth factor (anti-VEG...
ONL Therapeutics led recent ophthalmic fundraising efforts with a $65 million Series D round to continue advancing its small-molecule Fas inhibitor for retinal disease. Financing announced in the p...
Swiss company Oculis reported Aug. 27 in its Q2-2024 financial statement that it was shutting down the Phase III OPTIMIZE-2 trial of its OCS-01 eye drop candidate for postsurgical inflammation and ...
Visiox Pharmaceuticals announced Aug. 19 that it had agreed to merge with Ocuvex Therapeutics, a privately held company in New Hyde Park, New York. A Visiox news release said Ocuvex has a pipeline ...
The attorneys general for Colorado, Georgia, Michigan, North Carolina, Texas, and Washington have filed suit in federal district court against Regeneron Pharmaceuticals, claiming the drugmaker infl...
A new analysis of 2008 clinical study data has given a boost to Livionex’ topical drop candidate for cataracts, the John Moran Eye Center reported Aug. 16. The drop, called C-KAD, is a formulation ...
Bayer subsidiary BlueRock Therapeutics announced Sept. 3 that the US FDA had cleared its investigational new drug application for a Phase I/IIa trial of OpCT-001, an induced pluripotent stem cell (...
Belite Bio announced Sept. 1 that it had appointed Hendrik P.N. Scholl, MD, MA, as chief medical officer, effective immediately. Scholl specializes in inherited retinal and macular dystrophies, and...
BioCryst Pharmaceuticals, of Durham, North Carolina, announced Sept. 5 that it had appointed Donald S. Fong, MD, MPH, as the company’s new chief medical officer, effective immediately. Fong joined ...
Swiss company Oculis reported Aug. 27 in its Q2-2024 financial statement that it was shutting down the Phase III OPTIMIZE-2 trial of its OCS-01 eye drop candidate for postsurgical inflammation and ...
Italy’s SIFI announced Aug. 26 that the European Commission had approved Akantior (polihexanide 0.08%) drops for the treatment of Acanthamoeba keratitis (AK), a parasitic infection of the eye, in p...
The attorneys general for Colorado, Georgia, Michigan, North Carolina, Texas, and Washington have filed suit in federal district court against Regeneron Pharmaceuticals, claiming the drugmaker infl...
A new analysis of 2008 clinical study data has given a boost to Livionex’ topical drop candidate for cataracts, the John Moran Eye Center reported Aug. 16. The drop, called C-KAD, is a formulation ...
Visiox Pharmaceuticals announced Aug. 19 that it had agreed to merge with Ocuvex Therapeutics, a privately held company in New Hyde Park, New York. A Visiox news release said Ocuvex has a pipeline ...
Eyenovia announced in its Q2-2024 financial results that it planned to seek marketing clearance for an advanced Gen-2 Optejet microdoser. Eyenovia, of New York, said production was expected to begi...
China’s Ocumension Therapeutics announced Aug. 13 that it would acquire or secure Chinese rights to a portfolio of Alcon dry eye treatments and procedural drops. In exchange, Ocumension will issue ...
Ireland-based Mallinckrodt announced Aug. 6 that its H.P. Acthar Gel single-dose prefilled SelfJect injector was available in the US. The US FDA approved the supplemental new drug application for t...
China’s Ocumension Therapeutics announced Aug. 13 that it would acquire or secure Chinese rights to a portfolio of Alcon dry eye treatments and procedural drops. In exchange, Ocumension will issue ...
Japan’s Santen announced Aug. 6 that it had signed an agreement to license CBT-001, a topical pterygiumtreatment candidate from Cloudbreak Pharma. The deal covers the territories of Japan, South Ko...
Taiwan-based Formosa Pharmaceuticals announced Aug. 5 that it had agreed to license to Apotex exclusive rights to market clobetasol propionate 0.05% eye drops for postsurgical inflammation and pain...
ANI Pharmaceuticals announced June 24 that it would acquire Alimera Sciences, maker of Iluvien and Yutiq, in a deal worth $381 mil-lion up front. The deal is expected to close in late Q3-2024, the ...
RevOpsis Therapeutics, of San Carlos, California, announced June 17 that it had entered into a strategic manufacturing partnership with India’s Kemwell Biopharma. The deal aims to accelerate develo...
ANI Pharmaceuticals announced June 24 that it would acquire Alimera Sciences, maker of Iluvien and Yutiq, in a deal worth $381 million up front. The deal is expected to close in late Q3-2024, the c...
Nashville, Tennessee-based Harrow reported June 20 that it was moving closer to relaunching Triesence in 2024 after successfully achieving a production testing milestone. Triesence (triamcinolone a...
Ophthalmic manufacturer revenue in Q1-2024 totaled $11.0 billion. Revenue decreased 0.2 percent from the same quarter in 2023 and dropped 1.7 percent from Q4-2023. The total includes Market Scope e...
Opthea led recent ophthalmic fundraising efforts with a $113.2 million placement and entitlement offer, as it continues to advance its wet AMD candidate. Financing announced in the past four weeks ...
Merck, of Rahway, New Jersey, announced May 29 that it was acquiring Eyebiotech Limited (EyeBio) for an upfront payment of $1.3 billion and up to $1.7 billion in future milestone payments. The deal...
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
Belite Bio announced June 12 that Japanese regulators had granted the Sakigake, or pioneer therapy, designation to its lead candidate, tinlarebant, an oral tablet targeting Stargardt disease. Belit...
Merck, of Rahway, New Jersey, announced May 29 that it was acquiring Eyebiotech Limited (EyeBio) for an upfront payment of $1.3 billion and up to $1.7 billion in future milestone payments. The deal...
Outlook Therapeutics announced May 28 that the European Commission had granted marketing authorization for Lytenava, an ophthalmic formulation of bevacizumab for the treatment of wet age-related ma...
Partners Xbrane Biopharma, of Sweden, and Germany’s Stada announced May 10 that they had entered into an exclusive licensing agreement with biosimilar company Valorum Biologics to market their rani...
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
Taiwan-based Formosa Pharmaceuticals announced May 9 that it had entered into an exclusive licensing agreement with Tabuk Pharmaceuticals to market clobetasol propionate 0.05% eye drops for post-su...
Alcon reported May 13 that its Q1-2024 net sales were $2.4 billion, a 5 percent increase (+7 percent cc) over $2.3 billion in Q1-2023. Surgical net sales totaled $1.34 billion, consisting of $433 m...
Taiwan-based Formosa Pharmaceuticals announced May 9 that it had entered into an exclusive licensing agreement with Tabuk Pharmaceuticals to market clobetasol propionate 0.05% eye drops for post-su...
Outlook Therapeutics announced May 13 that it had submitted a marketing authorization application to the UK’s Medicines and Healthcare Products Regulatory Agency for ONS-5010 (bevacizumab gamma) fo...
OcuTerra Therapeutics, of Boston, Massachusetts, announced May 1 on LinkedIn that it would wind down operations. The company had been developing nesvategrast (OTT166 5%), an eye drop candidate for ...
Bausch + Lomb announced April 26 that the US FDA had approved a preservative-free formulation of Lumify redness reliever eye drops. Lumify is an over-the-counter formulation of low-dose brimonidine...
Swiss company Roche reported April 24 that Vabysmo sales in Q1-2024 were CHF 847 million ($926.5 million, calculated April 24, 2024), up from CHF 432 million (US $487 million) in Q1-2023. Vabysmo r...
Allergan and Novartis replaced Merck and Pfizer at the top of the glaucoma pharmaceuticals market a decade ago. Now it could be their turn to pass the baton. Allergan, acquired by AbbVie in 2020 an...
Viatris and Ocuphire Pharma announced April 1 the US launch of Ryzumvi (phentolamine ophthalmic solution) 0.75% for the reversal of pharmacologically induced mydriasis. The US FDA approved Ryzumvi ...
Retinal drug developer Outlook Therapeutics led recent ophthalmic fundraising efforts with two private placements, for proceeds totaling $164 million. Financing announced in the past four weeks tot...
Constance Okeke, MD, is helping to clear the confusion that can come from having multiple choices. “There are so many medicines coming into glaucoma that it can be difficult for a clinician to know...
A nor’easter storm that disrupted many travel itineraries failed to deter the nearly 600 industry personnel and clinicians who attended Eyecelerator ahead of the 2024 ASCRS meeting. This year’s con...
Wiley Chambers, MD, an ophthalmologist who conducted or supervised the review of ophthalmic drugs at the US FDA for 36½ years, retired from the agency Jan. 13, 2024. The 65-year-old is now serving ...
Nine large employers—including American Airlines, Aramark, General Motors, Target, and Lowe’s—have filed a new lawsuit against leading makers of generic drugs, claiming the drugmakers have engaged ...
The US Justice Department has accused New York-based Regeneron of fraudulently manipulating Medicare’s drug pricing process for Eylea, costing the Medicare system hundreds of millions of dollars. T...
Eyenovia reported April 8 that it is exploring strategic alternatives to maximize shareholder value, even as it rolls out Mydcombi for pupil dilation and prepares to launch its clobetasol propionat...
Ocular Therapeutix announced April 15 that its executive chairman, Pravin Dugel, MD, would assume the roles of president and chief executive officer, and that Antony Mattessich is stepping down, ef...
Nine large employers—including American Airlines, Aramark, General Motors, Target, and Lowe’s—have filed a new lawsuit against leading makers of generic drugs, claiming the drugmakers have engaged ...
The US Justice Department has accused New York-based Regeneron of fraudulently manipulating Medicare’s drug pricing process for Eylea, costing the Medicare system hundreds of millions of dollars. T...
Eyenovia reported April 8 that it is exploring strategic alternatives to maximize shareholder value, even as it rolls out Mydcombi for pupil dilation and prepares to launch its clobetasol propionat...
France’s Nicox announced that it had appointed Gavin Spencer, PhD, as chief executive officer, effective Feb. 28. Spencer was most recently executive vice president, chief business officer, and hea...
Wiley Chambers, MD, an ophthalmologist who conducted or supervised the review of ophthalmic drugs at the US FDA for 36 1/2 years, retired from the agency Jan. 13, 2024. The 65-year-old is now servi...
Nashville, Tennessee-based Harrow reported March 19 that its 2023 revenue was $130.2 million, a 47 percent increase over $88.6 million in 2022. The company generated record quarterly revenue in Q4-...
Ophthalmic manufacturer revenue in Q4-2023 totaled $11.2 billion. Revenue increased 0.4 percent from the same quarter in 2022 and increased 1.0 percent from Q3-2023. The total includes Market Scope...
Taiwan-based Formosa Pharmaceuticals announced March 4 that the US FDA had approved clobetasol propionate ophthalmic suspension 0.05% (APP13007) for inflammation and pain following ocular surgery. ...
Santen Pharmaceutical announced Feb. 28 that it had filed for marketing approval in Japan for DE-127 (0.025% atropine sulfate hydrate eye drop), designed to slow the progression of myopia. The prod...
Celanese announced the commercial launch Feb. 29 of Glaukos’ iDose TR intracameral travoprost implant for glaucoma. Celanese, a specialty materials and chemical company based in Dallas, Texas, prod...
Eyenovia and NovaBay Pharmaceuticals announced March 13 the signing of a co-promotion agreement to commercialize their prescription ophthalmic products. Under the agreement, NovaBay will market Eye...
Taiwan-based Formosa Pharmaceuticals announced March 4 that the US FDA had approved clobetasol propionate ophthalmic suspension 0.05% (APP13007) for inflammation and pain following ocular surgery. ...
Celanese announced the commercial launch Feb. 29 of Glaukos’ iDose TR intracameral travoprost implant for glaucoma. Celanese, a global specialty materials and chemical company based in Dallas, Texa...
AbbVie reported Feb. 20 that it had named Robert A. Michael—the company’s current president and chief operating officer—to succeed Richard A. Gonzalez as chief executive officer. Michael also will ...
Shanghai-based AffaMed Therapeutics announced Feb. 19 that the Singapore Health Sciences Authority had accepted its new drug application (NDA) for Dextenza (0.4 mg dexamethasone intracanalicular in...
Harrow reported Feb. 15 that it had licensed to Apotex exclusive marketing and distribution rights to Verkasia and over-the-counter Cationorm Plus in the Canadian market. In addition, Apotex will p...
France’s Nicox announced Feb. 8 that it had signed a deal granting Japanese drug company Kowa exclusive Japanese rights to develop and commercialize Nicox’ NCX 470 (0.1% bimatoprost) eye drop for g...
Apellis Pharmaceuticals announced Jan. 26 that, as expected, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) had recommended refusal of the company’s marketing...
Swiss company Roche reported Feb. 1 that global sales of Vabysmo for 2023 were CHF 2.36 billion ($2.78 billion, converted Feb. 1, 2024), a 299 percent increase (+324 percent cc) over CHF 591 millio...
Denmark’s Ascendis Pharma announced Jan. 29 that it had founded Eyconis, a separate company to develop and commercialize its ophthalmic assets globally. The company is launching with a $150 million...
Johnson & Johnson reported Jan. 23 that its full year 2023 global surgical vision revenue was $1.37 billion, a 4.9 percent increase (+5.8 percent cc) over $1.31 billion in 2022. Revenue was down 1....
Bayer subsidiary BlueRock Therapeutics announced Jan. 23 that it had exercised its option to license OpCT-001, an induced pluripotent stem cell (iPSC) derived cell therapy candidate for primary pho...
Privately held Abpro reported Jan. 22 that it will gain a listing on the Nasdaq through a merger with Atlantic Coastal Acquisition Corp. II, a special purpose acquisition company (SPAC) based in Ne...
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
New drugs to treat geographic atrophy (GA) hit the US market in 2023, but not without controversy. The US FDA approved Syfovre (pegcetacoplan injection) for commercial distribution for the treatmen...
The US FDA approved a new class of drugs to treat the signs and symptoms of dry eye disease in 2023. Two new treatments in the class, Miebo and Vevye, are both based on perfluorocarbon (PFC) molecu...
Vabysmo (faricimab), the new drug from Roche for exudative retinal disease that entered the market in 2022, reached “blockbuster” status in 2023. A blockbuster drug is defined as a drug with $1 bil...
The US FDA has scheduled the following Prescription Drug User Fee Act (PDUFA) target action dates for ophthalmic prescription and biologic drug candidates and those classified as drug/device combin...
Santen Pharmaceutical, Astellas Pharma, and Nitto Medic were among Japanese ophthalmic drugmakers facing delays in manufacturing drugs in the aftermath of a massive earthquake on New Year’s Day, ne...
Eyenovia announced Jan. 16 that it had reacquired the rights to pediatric myopia candidate MicroPine in the US and Canada from Bausch + Lomb. The investigational formulation of atropine, intended f...
Prime Minister Narendra Modi’s government has stepped up scrutiny of India’s pharmaceutical factories after being stung by a series of overseas deaths linked to Indian-made drugs. The news agency R...
Amneal Pharmaceuticals announced Jan. 10 that it had received US FDA approval for and launched generic fluorometholone eye drops. The product is indicated for the treatment of corticosteroid-respon...
German drugmaker Bayer announced Jan. 8 that the European Commission had granted marketing authorization in the EU for high-dose Eylea (aflibercept 8 mg, 114.3 mg/ml solution for injection) for the...
Harrow, of Nashville, Tennessee, reported Jan. 11 that dry eye drugVevye is now available in the US. Vevye (cyclosporine ophthalmic solution) 0.1% is a non‑preserved, twice-daily-dosed prescription...
Santen Pharmaceutical, Astellas Pharma, and Nitto Medic were among Japanese ophthalmic drugmakers facing delays in manufacturing drugs in the aftermath of a massive earthquake on New Year’s Day, ne...
Privately held Visiox Pharmaceuticals reported Dec. 27 that it will gain a listing on the Nasdaq through a merger with PowerUp Acquisition Corp., a special purpose acquisition company (SPAC) based ...
Genentech, a member of the Roche Group, reported Dec. 12 that it had appointed Ashley Magargee as chief executive officer. Magargee has been serving as interim CEO since Alexander Hardy stepped dow...
The White House on Dec. 7 rolled out a framework to use the government’s march-in rights on drugs developed with taxpayer dollars, saying if drugmakers refuse to make their products available at an...
Ophthalmic manufacturer revenue in Q3-2023 totaled $11.1 billion. Revenue increased 3.4 percent from the same quarter in 2022 and decreased 2.7 percent from Q2-2023. The total includes Market Scope...
2023 was a busy year for the US FDA in ophthalmology. Among the 11 drug products approved were the first two therapies in the US to treat geographic atrophy; two new drops for dry eye; and a second...
EyePoint Pharmaceuticals reported Dec. 4 that EYP-1901, a sustained-release anti-VEGF implant candidate, met its primary endpoint and all secondary endpoints in the Phase II DAVIO 2 trial in wet ag...
Genentech and Nvidia reported Nov. 21 that the two companies had formed a multi-year strategic research collaboration to accelerate Genentech’s proprietary algorithms and speed drug development. Ge...
Japanese drugmaker Santen Pharmaceutical announced Nov. 17 that the European Commission had approved its marketing authorization application for preservative-free Catiolanze (cationic emulsion of l...
Aldeyra Therapeutics announced Nov. 1 that AbbVie had signed an exclusive option agreement to license to develop, manufacture, and commercialize reproxalap, Aldeyra’s candidate in development for d...
UK-headquartered Immunocore reported Nov. 7 that its Q3-2023 net revenue from Kimmtrak (tebentafusp) was £49.7 million ($60.7 million, converted at a rate of £1.00 to $1.2214), an increase of 9 per...
Kodiak Sciences announced Nov. 6 that it would restart its tarcocimab tedromer development program after strong positive results from a Phase III trial in diabetic retinopathy (DR). The Palo Alto, ...
Outlook Therapeutics reported Nov. 2 that it plans to hold another clinical trial of Lytenava, an ophthalmic formulation of bevacizumab, for wet age-related macular degeneration (AMD), in the wake ...
Regeneron of Tarrytown, New York, reported Nov. 2 that its Q3-2023 US revenue for Eylea (aflibercept) 2 mg and Eylea HD (a higher dose of aflibercept at 8 mg) was $1.49 billion, with Eylea HD accou...
Ocuphire Pharma announced Nov. 1 that it had appointed George Magrath, MD, as chief executive officer and a member of its board of directors. Magrath succeeds Rick Rodgers, interim CEO and presiden...
Australian company Opthea announced Oct. 27 that the company’s chief executive officer, Megan Baldwin, PhD, will transition to founder and chief innovation officer, and that US-based Frederic Guera...
Swiss company Roche reported Oct. 19 that Q3-2023 Vabysmo sales were CHF 656 million ($732 million, converted Oct. 19), a 309 percent increase over CHF 173 million in Q3-2022. Vabysmo was approved ...
Genentech, a member of the Roche Group, announced Oct. 27 that the US FDA had approved Vabysmo (faricimab-svoa) for the treatment of macular edema following retinal vein occlusion (RVO). RVO is the...
Stuart Therapeutics announced Oct. 18 that it had granted Glaukos exclusive worldwide rights to develop and commercialize Stuart’s ST-113 drug candidate for neuroprotection in glaucoma. ST-113 is a...
Swiss company Endogena Therapeutics announced Oct. 24 that the US FDA had cleared its investigational new drug (IND) application for a clinical trial of EA-2351, a regenerative treatment candidate ...
4D Molecular Therapeutics announced Oct. 23 that the European Medicines Agency had granted Priority Medicine (PRIME) designation for 4DMT’s intravitreal gene therapy candidate 4D-150 in wet age-rel...
Annexon announced Oct. 24 that the European Medicines Agency had granted Priority Medicine (PRIME) designation to ANX007 for the treatment of geographic atrophy (GA) secondary to age-related macula...
Swiss drugmaker Roche reported in its Q3-2023 earnings call on Oct. 19 that it had ended development of vicasinabin (RG7774), an oral candidate for non-proliferative diabetic retinopathy, after com...
Swiss company Novartis spun out Sandoz, its generics and biosimilars business, on Oct. 4. Sandoz is a leading provider in the US of generic ophthalmic drugs for a wide range of eye diseases. It has...
Orasis Pharmaceuticals announced Oct. 18 that the US FDA had approved Qlosi (pilocarpine hydrochloride 0.4%), a twice-daily eye drop for presbyopia. The company said it expected Qlosi, a preservati...
Specialty pharma company Padagis announced Oct. 13 the launch of its brinzolamide ophthalmic suspension, a generic version of Novartis’ Azopt for glaucoma. Padagis with offices in the US and Israel...
China’s Innovent Biologics announced Oct. 8 that the first patient had been dosed in a Phase III trial of efdamrofusp alfa (IBI302), a recombinant fully human anti-VEGF and anti-complement bispecif...
Pine Pharmaceuticalsannounced Oct. 2 that it had issued two voluntary recalls of drug products that include ophthalmic drugs. Repackaged bevacizumab appears to be the most affected ophthalmic produ...
Melt Pharmaceuticals announced Sept. 26 that it had entered into an exclusive development and license agreement with Catalent to use Catalent’s Zydis orally disintegrating tablet with MELT-300, a s...
Viatris and Ocuphire Pharma announced Sept. 27 that the US FDA had approved Ryzumvi (phentolamine ophthalmic solution) 0.75% for the reversal of pharmacologically induced mydriasis. Ryzumvi is expe...
Théa Pharma, the US subsidiary of France’s Laboratoires Théa, announced the launch Sept. 26 of once-daily Iyuzeh (latanoprost ophthalmic solution) 0.005% in the US market. Iyuzeh is the first prese...
Iveric Bio, an Astellas company, reported on Sept. 18 positive 24-month topline results from the Phase III GATHER2 trial of Izervay (avacincaptad pegol), its treatment for geographic atrophy (GA) s...
Mati Therapeutics, of Austin, Texas, reported Sept. 12 that it had completed a 10 thousand square foot facility in Bryan, Texas, to manufacture the company’s Evolute sustained drug delivery platfor...
Swiss company Novartis reported Sept. 15 that its shareholders had approved its spinoff of Sandoz, its generics and biosimilars business. The target date for the spinoff is Oct. 4. Sandoz is a lead...
Precision Dropper, of Twin Falls, Idaho, on Sept. 15 introduced its universal adapter for eye drop bottles, designed to increase patient comfort and reduce waste when administering topical ocular m...
Brim Biotechnologies, of Taiwan, led recent ophthalmic fundraising efforts with a $45.8 million rights issue to advance its lead dry eye candidate. Funding announced in the past four weeks totaled ...
The Centers for Medicare & Medicaid Services (CMS) issued J-codes in Q2-2023 for Syfovre and Acthar Gel and an A-code for Luminopia’s software for amblyopia treatment. The billing codes take effect...
Apotex announced Sept. 5 that it had launched its generic brimonidine tartrate 0.1% ophthalmic solution in the US. Brimonidine is an alpha-adrenergic receptor agonist indicated for the reduction of...
No ophthalmic pharmaceutical or biologic product made the list of US Medicare Part D drugs subject to price negotiations in 2026. The White House published the list on Aug. 29. Most ophthalmic drug...
Apotex announced Sept. 5 that it had launched its generic brimonidine tartrate 0.1% ophthalmic solution in the US. Brimonidine is an alpha-adrenergic receptor agonist indicated for the reduction of...
Outlook Therapeutics reported on Aug. 30 that the US FDA had issued a complete response letter to the company’s biologics license application (BLA) for Lytenava, an ophthalmic formulation of bevaci...
Regeneron Pharmaceuticals announced Aug. 18 that the US FDA had approved Eylea HD, its high-dose formulation of aflibercept, for wet age-related macular degeneration (AMD), diabetic macular edema (...
Apellis Pharmaceuticals issued a safety update Aug. 22 regarding cases of rare, vision-threatening retinal vasculitis associated with injections of Syfovre (pegcetacoplan injection), its treatment ...
Indian drugmaker Lupin announced Aug. 16 that the US FDA had approved its abbreviated new drug application for bromfenac ophthalmic solution, 0.09%, a generic equivalent of Bausch + Lomb’s Bromday....
Ophthalmic drugs are not expected to make the list of drugs subject to US Medicare price negotiations in 2026 or 2027, according to a study published in March 2023 by the Journal of Managed Care & ...
Tarsus Pharmaceuticals announced July 25 that the US FDA had approved Xdemvy (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis. Xdemvy, formerly known as TP-03, is the ...
Iveric Bio, an Astellas company, announced Aug. 4 that the US FDA had approved Izervay (avacincaptad pegol) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneratio...
Kriya Therapeutics led recent ophthalmic fundraising efforts with $150 million in a Series C financing to advance its gene therapy candidates. Funding announced in the past four weeks totaled $456....
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
Two recent drug launches show that there still is plenty of opportunity for new products in retinal pharmaceuticals despite the dominance of Eylea in exudative retinal disease. Vabysmo sales took o...
New York’s Icahn School of Medicine at Mount Sinai announced July 5 that it had launched the Center for Ophthalmic Artificial Intelligence and Human Health. The center will incorporate AI into educ...
Iveric Bio, an Astellas company, announced Aug. 18 that the European Medicines Agency (EMA) had accepted for review its marketing authorization application for avacincaptad pegol, a complement C5 i...
Alcon reported Aug. 15 that its Q2-2023 net sales totaled $2.4 billion, a 9 percent increase (+12 percent cc) over $2.2 billion in Q2-2022. Surgical net sales for implantables, consumables, and equ...
Taiwan-based Formosa Pharmaceuticals announced Aug. 16 that Eyenovia had licensed US rights to Formosa’s APP13007 (clobetasol propionate ophthalmic nanosuspension, 0.05%) for inflammation and pain ...
Regeneron Pharmaceuticals reported Aug. 10 positive, two-year, topline data from the pivotal PULSAR trial investigating aflibercept 8 mg in patients with wet age-related macular degeneration (AMD)....
Iveric Bio, an Astellas company, announced Aug. 4 that the US FDA had approved Izervay (avacincaptad pegol) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneratio...
Swiss company Oculis reported Aug. 8 positive topline results from a Phase III trial of its OCS-01 eye drop for inflammation and pain following ocular surgery. OCS-01 is a high-concentration (15 mg...
The Missouri University of Science and Technology announced July 31 that one of its professors researching glaucoma treatments was awarded a grant from the National Institutes for Health that will ...
Amneal Pharmaceuticals announced July 26 that it had submitted an abbreviated new drug application (NDA) to the US FDA for bimatoprost ophthalmic solution 0.01%, a generic version of Lumigan, to tr...
Kodiak Sciences reported July 24 that it would discontinue development of tarcocimab (KSI-301) after the anti-VEGF candidate failed to meet the primary endpoint of non-inferiority to aflibercept in...
Lasers: Impressive six-year results for SLT and new lasers fed growing interest in laser therapy for OHT and open-angle glaucoma. Personalized medicine and interventional glaucoma: Whether called “...
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.